Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00200473 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients
A Phase 3 study of Hypertension, sponsored by Mylan Bertek Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT00200473: Completed Phase 3 study of Hypertension, sponsored by Mylan Bertek Pharmaceuticals.
NCT00200473 is a Phase 3 study of Hypertension that has completed, run by Mylan Bertek Pharmaceuticals. The registered enrollment target is 800 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00200473, a Phase 3 study of Hypertension, has completed, sponsored by Mylan Bertek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to determine the safety, efficacy and superiority of nebivolol to placebo for the treatment of elevated blood pressure in patients with mild to moderate hypertension.
Conditions Studied
Interventions
- DRUG Nebivolol
Study Locations (1)
West Virginia
- Mylan Pharmaceuticals Inc. - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00200473
The ClinicalTrials.gov registry entry for NCT00200473 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (77% lower). The listed sponsor is Mylan Bertek Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Nebivolol is the first listed.
NCT00200473 reports 1 study location spanning 1 distinct geographic area - top geographies include West Virginia.
Frequently Asked Questions
What is clinical trial NCT00200473 about?
NCT00200473 is a clinical study titled "A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients". A study to determine the safety, efficacy and superiority of nebivolol to placebo for the treatment of elevated blood pressure in patients with mild to moderate hypertension.
What is the current status of trial NCT00200473?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2001-09. Estimated completion is 2003-03.
What conditions does trial NCT00200473 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00200473?
The interventions under investigation include: Nebivolol (DRUG).
Who is sponsoring clinical trial NCT00200473?
This trial is sponsored by Mylan Bertek Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00200473 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.